

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee

Summary of Main Points from the Meeting held on the 8th July 2013

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the June 2013 meeting were approved and will be circulated.

3. Matters Arising

The Committee noted the matters arising from the previous meeting.

4. New Medicines Applications

Formulary applications

- **Lixisenatide Injection (Lyxumia[®])**

Decision: Not approved

Lyxumia[®] is indicated for the treatment of adults with Type 2 Diabetes Mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Lyxumia[®] is not currently included on the NWL integrated formulary. A decision was made to delay adding it to the local formulary until it has been approved for addition to the NWL integrated formulary as patients' continued treatment is dependent on GPs being able to undertake prescribing in the primary care setting. The Diabetes Team will therefore submit an application for consideration to the NWL Integrated formulary panel.

- **Rotavirus Oral Vaccine (Rotarix[®])**

Decision: Approved

Rotarix[®] is indicated for the active immunisation of infants aged 6 to 24 weeks for prevention of gastro-enteritis due to rotavirus infection in line with DH childhood vaccination programme.

- **Vaccines for supply via Chelsea Vaccine Clinic**

Decision: Not approval

An application was considered to include the following vaccines:

- Rabies
- Japanese Encephalitis
- Tick Borne Encephalitis
- Yellow Fever
- Varicella-Zoster

to be added to the local formulary to support the running of the new Chelsea Vaccine Clinic. Approval was deferred until the panel are satisfied that the Governance issues relating to the setting up and running of this clinic are being managed appropriately. Further discussion required.

Individual funding requests

Decision: Noted

- **Eltrombopag IV for thrombocytopenia associated with Hepatitis C treatment**

Approved by the Pharmaco-economic Board.

Action: To follow up issue relating to the funding of this treatment with the Lead Clinical Directorate Pharmacist for Medicine.

Ex-panel

Decision: Approved

Indapamide 2.5mg Tablets

Decision: Approved

As a diuretic to support continued supply where patients are admitted taking this drug.

- **Mesalazine 800mg SR tablets (Octasa[®])**

Decision: Approved

SR Mesalazine of choice in primary care and more cost effective than Asacol MR[®]. There is a plan to switch over to using this formulation in Gastroenterology.

- **Taurolock[®]**

Decision: Approved

Used to lock central IV lines in patients receiving parenteral nutrition (PN) who are at risk of recurrent line infections.

5. NICE Guidance on developing and updating local formularies

NICE Guidance on developing and updating local formularies

A status report was provided on the updated action plan as at July 2013.

The action plan has currently 2 outstanding actions relating to the publishing of medicines Committee meeting summaries and the table of formulary status of NICE positive TAGs on the public Trust internet website. These actions are due to be completed next week. The final completed action plan will be forwarded to the Quality Committee for noting.

6. Medicines Management/Trust Medicines Policy

Trust Medicines Policy – Section 21. Patient Group Directions

Decision: Approved

Updated to detail that audit summaries should be sent to the Divisional Lead Nurse.

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

e-FP10 project Patient Information leaflet

Decision: Approved

A progress report was provided on the e-FP10 project pilot that started in the Trust on 01/07/13. The patient Information leaflet that has been compiled for use as part of the pilot was approved by the panel.

7. Medicines Management Annual Report 2012/13

• **IV Administration monograph - Immunoglobulin IV**

Decision: Approved

This report summarises the activities of committees responsible for the management of medicines at Chelsea and Westminster Hospital NHS Foundation Trust describes developments throughout the 2012-13 year and reports on the results of external assessments. The report was updated following comments received at the Medicines Committee meeting in June to include the following:

- Section relating to VTE
- Section relating to NPSA - Never Events Assurance Reports
- Panel members names and titles
- Titles of Appendices in contents table
- Details of the BMJ award for the CLAHRC project - Improving medication at Discharge – Closing the loop.

The updated report was approved pending a further minor amendment.

8. NICE TA Guidance

Nice Guidance June 2013

• **TA287 Rivaroxaban for treating PE and preventing VTE**

Rivaroxaban is recommended as an option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism in adults.

Update to formulary required

• **TA288 – Dapagliflozin in combination therapy for Type 2 Diabetes**

Dapagliflozin is recommended for use in combination with other therapies in particular circumstances in Type 2 Diabetes.

9. IVIG Update

The panel noted the IVIG report.

The panel noted the IVIG report.

There were 8 IVIG issues in June 2013, with 4 new requests.

- One for Guillain Barre Syndrome (Red indication)
- One for Kawasaki Disease (Red indication)
- One for TENS (Red indication)
- One for Myasthenia Gravis (Blue indication)

10. Items for Noting

• **Medicines Management programme for development 2013/14**

Noted.

• **Drugs Sub-Committee Meeting minutes - May 2013**

Noted.

• **Category A&B UMPs**

Noted

• **MHRA Drug Safety Update - June 2013**

Noted

Further actions to be undertaken relating to management of diclofenac use in Surgery in light of its contraindications in particular cardiac conditions.

11. Papers to go to the Trust Quality Committee

The following papers should be sent to the Trust Quality Committee:

- Medicines Committee Summary Notes - June 2013
- NICE Guidance: Developing and updating local formularies - Action plan
- Medicines Management Annual Report 2012/13

12. AOB

Medicines Policy – Appendix 3. Medicines Management Training Programme

Decision: Approved

Updated to include antibiotic and VTE training and training undertaken by non-medical prescribers who prescribe and radiographers and physiotherapists who administer medicines.

13. Date of the next meeting

Monday 8th September 2013, 8.00 – 9.00 Boardroom, Lower Ground Floor.

Closing date for papers: Friday 16th August 2013

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**